---
document_datetime: 2023-11-29 15:06:32
document_pages: 30
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/advate-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: advate-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 17.5220568
conversion_datetime: 2025-12-19 03:17:16.301248
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Advate

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0121               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)  | 24/11/2023                          |                                             | Labelling                        |           |
| II/0119/G            | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or | 20/07/2023                          |                                             | SmPC and Labelling               |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate A.7 - Administrative change - Deletion of manufacturing sites   |            |     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0120/G | This was an application for a group of variations. B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                                                                                                                                   | 22/06/2023 | n/a |

<div style=\"page-break-after: always\"></div>

|                    | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/2200/ 202208 | Periodic Safety Update EU Single assessment - octocog alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 14/04/2023 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0117            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 04/07/2022 | 15/03/2023 | SmPC and PL |                                   |
| WS/2218/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products | 12/05/2022 | 15/03/2023 | SmPC        |                                   |
| WS/2189            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and                                                                                                                                                                                                                                                                  | 24/02/2022 | 15/03/2023 | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

|           | biological/immunological medicinal products                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |          |                         |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-------------------------|
| IA/0116/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites | 08/02/2022 | 15/03/2023 | Annex II | (excluding manufacturer |
| IB/0114   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 04/01/2022 | n/a        |          |                         |
| IB/0112   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 03/06/2021 | n/a        |          |                         |

<div style=\"page-break-after: always\"></div>

|                    | or addition) for the AS or a starting material/intermediate                                                                                                                                                       |            |            |                        |                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IB/0110            | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                              | 26/03/2021 | n/a        |                        |                                   |
| IB/0111            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                    | 24/02/2021 | 24/02/2022 | SmPC, Labelling and PL |                                   |
| IB/0109            | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate      | 19/10/2020 | n/a        |                        |                                   |
| IA/0108            | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                        | 21/08/2020 | n/a        |                        |                                   |
| II/0107            | B.I.a.4.d - Change to in-process tests or limits applied during the manufacture of the AS - Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the AS | 23/07/2020 | n/a        |                        |                                   |
| PSUSA/2200/ 201908 | Periodic Safety Update EU Single assessment - octocog alfa                                                                                                                                                        | 17/04/2020 | n/a        |                        | PRAC Recommendation - maintenance |
| T/0106             | Transfer of Marketing Authorisation                                                                                                                                                                               | 21/02/2020 | 01/04/2020 | SmPC, Labelling and    |                                   |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                       |            |            | PL                               |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| WS/1723 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.c.z - Container closure system of the AS - Other variation                                                                          | 26/03/2020 | n/a        |                                  |
| IA/0105 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                         | 20/12/2019 | 01/04/2020 | SmPC, Annex II, Labelling and PL |
| WS/1634 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB | 12/09/2019 | n/a        |                                  |
| II/0100 | B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                                                                                | 12/09/2019 | n/a        |                                  |
| WS/1657 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor                                           | 04/07/2019 | n/a        |                                  |

<div style=\"page-break-after: always\"></div>

|         | changes to an approved test procedure                                                                                                                                                                                                                                                                     |            |            |      |                                                                                                                                                                                                                                   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0099 | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                | 10/04/2019 | n/a        |      |                                                                                                                                                                                                                                   |
| IB/0098 | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                | 29/03/2019 | n/a        |      |                                                                                                                                                                                                                                   |
| IB/0097 | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                              | 14/01/2019 | n/a        |      |                                                                                                                                                                                                                                   |
| IB/0096 | B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                             | 06/11/2018 | n/a        |      |                                                                                                                                                                                                                                   |
| IB/0095 | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                               | 02/10/2018 | n/a        |      |                                                                                                                                                                                                                                   |
| II/0092 | Update of section 5.1 of the SmPC in order to add new data on immune tolerance induction (ITI). This update follows final results from study PASS-INT- 004; this was a prospective, multi-centre, uncontrolled, open-label, non-interventional post- authorization safety surveillance study conducted to | 06/09/2018 | 06/06/2019 | SmPC | A non-interventional prospective registry (PASS-INT-004) documented immune tolerance induction (ITI) in 44 paediatric and adult subjects of whom 36 completed ITI therapy. The data showed that immune tolerance may be achieved. |

<div style=\"page-break-after: always\"></div>

|         | evaluate Advate in ITI therapy in subjects with moderate or severe hemophilia A (baseline factor VIII â‰¤ 2%) and a high titer (> 5 BU) inhibitor to FVIII. The RMP version 16.0 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                         |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0091 | Update of section 4.2 of the SmPC in order to remove a statement that the use of 2 ml presentations has not been documented for paediatric subjects below 2 years of age. This update follows final results from study 061101 listed as a category 3 study in the RMP; this was a prospective, non-interventional, post-marketing surveillance study that assessed the safety and efficacy of Advate reconstituted in 2 ml of sterile water for injection during routine clinical practice in the EU. The Package Leaflet is updated accordingly. The RMP version 15.1 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 14/06/2018 | 06/06/2019 | SmPC and PL | The study did not support a higher risk of hypersensitivity or infusion-related reactions of the lower injection volume 2 ml in children. No new safety signals were identified. Advate 2 ml was well tolerated in patients <12 years old, none of the adverse events were considered related by the investigators. No FVIII inhibitor development was observed. No differences between the <2 years age group and subjects >2 and <12 years of age was determined with regard to safety and treatment efficacy. |
| IA/0094 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 17/05/2018 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| II/0090   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                   | 08/03/2018   | n/a        |             |                                                                                         |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-----------------------------------------------------------------------------------------|
| II/0088   | Submission of the final report from study 061301 (China PTP). This is an interventional, open-label study aimed to evaluate the efficacy and safety of Advate in the treatment of previously treated patients with haemophilia A. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                 | 18/01/2018   | n/a        |             |                                                                                         |
| II/0089   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                   | 11/01/2018   | n/a        |             |                                                                                         |
| A31/0078  | Pursuant to Article 31 of Directive 2001/83/EC, Germany initiated a procedure on 6 July 2016 based on concerns resulting from the evaluation of data from pharmacovigilance activities. The PRAC was requested to assess the potential impact of the results of the SIPPET study (which concluded that recombinant factor VIII medicines had a higher incidence of inhibitor development than plasma-derived medicines), and to issue a recommendation as to whether the marketing authorisations of these products should be maintained, varied, suspended or revoked. The EMA | 14/09/2017   | 24/11/2017 | SmPC and PL | Please refer to the assessment report: human coagulation factor VIII - EMEA/H/A-31/1448 |

<div style=\"page-break-after: always\"></div>

|           | concluded in September 2017 that there is no clear and consistent evidence of a difference in the incidence of inhibitor development between the two classes of factor VIII medicines: those derived from plasma and those made by recombinant DNA technology. Due to the different characteristics of individual products within the two classes, EMA concluded that the risk of inhibitor development should be evaluated individually for each medicine, regardless of class. The risk for each product will continue to be assessed as more evidence becomes available.                                                                                                 |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0082/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 12/10/2017 | n/a |

<div style=\"page-break-after: always\"></div>

|                    | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS   |            |            |                  |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|-----------------------------------|
| II/0085            | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                                                                                                                                                                              | 14/09/2017 | n/a        |                  |                                   |
| IB/0084            | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                | 28/06/2017 | n/a        |                  |                                   |
| N/0086             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                    | 14/06/2017 | 24/11/2017 | Labelling and PL |                                   |
| PSUSA/2200/ 201608 | Periodic Safety Update EU Single assessment - octocog alfa                                                                                                                                                                                                                                                                                                                                                                                                                                          | 05/05/2017 | n/a        |                  | PRAC Recommendation - maintenance |
| II/0083/G          | This was an application for a group of variations. B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products                                                                                                                                                                                                                                                                                                                        | 21/04/2017 | n/a        |                  |                                   |

<div style=\"page-break-after: always\"></div>

|         | B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                             |            |     |           |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IB/0080 | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                   | 12/01/2017 | n/a |           |
| IB/0079 | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                        | 19/08/2016 | n/a |           |
|         | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test A.7 - Administrative change - Deletion of | 17/08/2016 | n/a | IB/0077/G |

<div style=\"page-break-after: always\"></div>

| IB/0076/G   | This was an application for a group of variations. B.I.a.z - Change in manufacture of the AS - Other variation B.I.a.z - Change in manufacture of the AS - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                              | 27/04/2016   | n/a   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IB/0075     | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 02/02/2016   | n/a   |
| IB/0073/G   | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation | 03/09/2015   | n/a   |

<div style=\"page-break-after: always\"></div>

|           | - Change in the specification parameters limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                            |            |            |          | B.I.b.1.z and/or   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|--------------------|
| IA/0074   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                              | 11/08/2015 | n/a        |          |                    |
| II/0065/G | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test already authorised | 23/07/2015 | n/a        |          | procedure is       |
| IA/0072/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name of a manufacturer or an ASMF holder                                                                                                                          | 01/07/2015 | 24/06/2016 | Annex II | and/or address     |

<div style=\"page-break-after: always\"></div>

|             | starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                   |            |            |                 | or supplier of the AS,   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------|
| IB/0071     | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 18/06/2015 | n/a        |                 |                          |
| IB/0070     | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                          | 17/06/2015 | n/a        |                 |                          |
| IAIN/0069/G | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location | 02/06/2015 | 24/06/2016 | Annex II and PL |                          |
| IB/0066     | B.I.b.2.e - Change in test procedure for AS or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 23/04/2015 | n/a        |                 |                          |

<div style=\"page-break-after: always\"></div>

|                    | starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                            |            |            |                        |                                                                                            |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------|
| N/0067             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                         | 16/03/2015 | 24/06/2016 | PL                     |                                                                                            |
| IB/0064            | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                              | 10/02/2015 | n/a        |                        |                                                                                            |
| PSUSA/2200/ 201402 | Periodic Safety Update EU Single assessment - octocog alfa                                                                                                                                                                                                                                                                                                                                                                                               | 09/10/2014 | n/a        |                        | PRAC Recommendation - maintenance                                                          |
| II/0060            | Introduction of a post approval change management protocol related to the Active Substance B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                                        | 25/09/2014 | n/a        |                        | Introduction of a post approval change management protocol related to the Active Substance |
| IAIN/0063/G        | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 06/08/2014 | 15/01/2015 | SmPC, Labelling and PL |                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within   |            |            |                     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|
| II/0059/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 24/07/2014 | 15/01/2015 | SmPC, Labelling and |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.1.c. Addition of a New packaging site B.II.b.z. Cange in the manufacturing process B.IV.z introduction of the alternative BAXJECT III reconstitution system B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.z - Change in manufacture of the Finished Product - Other variation B.IV.z - Quality change - Change in Medical Devices -   |            |            | PL       |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|
| IB/0061   | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 09/07/2014 | n/a        |          |
| IB/0058   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 07/03/2014 | n/a        |          |
| II/0053/G | This was an application for a group of variations. Introduction of additional new active substance manufacturing and release testing site                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 23/01/2014 | 15/01/2015 | Annex II |

<div style=\"page-break-after: always\"></div>

|         | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product   |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0057 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                       | 16/01/2014 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| R/0052  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                   | 24/10/2013 | 20/12/2013 | SmPC, Labelling and PL | Advate contains octocog alfa, a recombinant human coagulation Factor VIII produced by recombinant DNA technology in Chinese Hamster Ovary cells and belongs to the pharmacotherapeutic group of blood coagulation Factor VIII (ATC code: B02BD02). It was first approved in the EU in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) on 02 March 2004 and renewed on 26 February 2009. This is the 2nd renewal of the Marketing Authorisation for Advate. An overview of the knowledge and information submitted related to the quality, safety and efficacy aspects of the product reconfirmed the positive benefit- risk ration in the approved indication. The risk management plan is in place and is considered acceptable. The CHMP considers that the renewal can be granted with unlimited validity. |

<div style=\"page-break-after: always\"></div>

| IA/0055/G   | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                     | 08/11/2013   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0049     | Update of sections 4.4, 4.8 and 5.1 to update and clarify information on hypersensitivity and inhibitor occurrence and amend frequencies in the table of adverse drug reactions following the results of an integrated safety analysis from completed clinical trials. The Package Leaflet was proposed to be updated accordingly. The Labelling was update to improve clarity on the information on the expiry date after 6 months storage at room temperature. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 19/09/2013   | 20/12/2013 | SmPC, Annex II, Labelling and PL | Update of sections 4.4, 4.8 and 5.1 to update and clarify information on hypersensitivity and inhibitor occurrence and amend frequencies in the table of adverse drug reactions following the results of an integrated safety analysis from 12 completed clinical trials. The Package Leaflet was proposed to be updated accordingly. The Labelling was update to improve clarity on the information on the expiry date after 6 months storage at room temperature. Changes were also implanted for compliance with the core SmPC for FVIII products (Guideline on core SmPC for human plasma derived and recombinant coagulation factor VIII products; EMA/CHMP/BPWP/1619/1999 Rev.1) and QRD template version 9.0. |
| IA/0054/G   | This was an application for a group of variations. B.III.2.a.2 - Change of specification(s) of a former non Pharmacopoeial substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non Pharmacopoeial substance to comply with the                                                                                                                                                                                                                                                               | 23/08/2013   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|           | Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0051/G | This was an application for a group of variations. Changes to the active substance manufacturing process B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal | 25/07/2013 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0050   | Update of sections 5.1 to include data from study 060201 where an individualised pharmacokinetic guided dosing regimen and a standard prophylactic dosing regimen were compared and update of section 5.2 of the SmPC in order to include PK data from an integrated summary of completed pharmacokinetic studies. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is being brought in line with the latest QRD template version 9.0.                                                                                         | 30/05/2013 | 20/12/2013 | SmPC, Annex II and PL | In study 060201, two long-term prophylaxis treatment schemes have been compared in 53 PTPs: an individualised pharmacokinetic guided dosing regimen (within a range of 20 to 80 IU of factor VIII per kg body weight at intervals of 72 Â± 6 hours, n=23) with a standard prophylactic dosing regimen (20 to 40 IU/kg every 48 Â±6 hours, n=30) . The pharmacokinetic guided dosing regimen (according to a specific formula) was targeted to maintain factor VIII trough levels â‰¥ 1% at the inter-dosing interval of 72 hours. The data from this study demonstrate that the two prophylactic dosing regimens are comparable in terms of |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                           |            |     | reduction of bleeding rate. These data were included in section 5.1 of the SmPC. Detailed pharmacokinetic results from an integrated summary of 6 completed pharmacokinetic studies were also included in section 5.2 of the SmPC.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0048   | Changes to the active substance manufacturing process B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol                                                                                                                                                                                                      | 13/12/2012 | n/a |                                                                                                                                                                                                                                      |
| IB/0046   | B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                       | 29/05/2012 | n/a |                                                                                                                                                                                                                                      |
| II/0045/G | This was an application for a group of variations. Change to the active substance specification and minor change to a test procedure. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 24/05/2012 | n/a |                                                                                                                                                                                                                                      |
| IAIN/0047 | C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the                                                                                                                                                                                                                                                                                                                                                               | 11/05/2012 | n/a |                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|           | safety database                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                        |                                                                                                                                                                                                                                                                                                               |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0044   | B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products                                                                                                                                                                                                                                                                                                                                                                                                                                            | 16/02/2012 | 10/09/2012 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                               |
| X/0041    | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 20/10/2011 | 19/12/2011 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                               |
| II/0043/G | This was an application for a group of variations. Change to the active substance testing and specification. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change (replacement) to a biological/immunological/ immunochemical test method or a method using a biological reagent for a biological AS B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method | 15/12/2011 | 15/12/2011 |                        |                                                                                                                                                                                                                                                                                                               |
| II/0038   | Update of sections 4.2, 4.4 and 5.1 of the SmPC to include information on immune tolerance induction. The MAH has taken the opportunity to update sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in line with the revised SmPC guideline with consequential changes to the Package Leaflet. The                                                                                                                                                                                                                                                                     | 19/05/2011 | 29/06/2011 | SmPC, Annex II and PL  | Following the currently valid Clinical Guideline, the MAH provided data from clinical studies on \"Immune tolerance induction (ITI). The available information regarding ITI is described within section 5.1 of the SPC with the following wording: \"Data on Immune Tolerance Induction (ITI) in patients with |

<div style=\"page-break-after: always\"></div>

|         | addresses of the local representatives have also been removed from the package leaflet. Annex II has been updated to reflect the new version of the Risk Management Plan (RMP version 10.0) as well as other minor editorial changes. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |            |            | inhibitors have been collected. Within a sub-study of PUP- study 060103, ITI-treatments in 11 PUPs were documented. Retrospective chart review was done for 30 subjects on ITI (study 060703) and collection of Registry data is on-going.\" Besides the identified risk of catheter-related complications no further risks for the patient have been identified. The following wording is proposed to be introduced into section 4.4 of the SPC:\"If central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bacteremia and catheter site thrombosis should be considered.\"   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0042 | B.III.2.a.2 - Change of specification(s) of a former non Pharmacopoeial substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material                                                                                                                                                                                              | 02/03/2011 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0039 | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                         | 04/10/2010 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0040 | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                            | 02/09/2010 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0037 | Additional drug product manufacturing site for Advate 2000 IU and 3000 IU. Quality changes                                                                                                                                                                                                                                                                                                     | 22/04/2010 | 28/04/2010 | Additional drug product manufacturing site for Advate 2000 IU and 3000 IU.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| II/0036   | Changes in the manufacturing process of the active substance. Change(s) to the manufacturing process for the active substance   | 19/11/2009   | 25/11/2009   |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|---------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0033   | Change in shelf life of finished product. Quality changes                                                                       | 23/04/2009   | 29/05/2009   | SmPC, Labelling and PL           | Change in shelf life of finished product.                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0035   | IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release                            | 03/04/2009   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0034   | IB_42_b_Change in storage conditions of the finished/diluted/reconstituted product                                              | 30/03/2009   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0030   | Approval of changes to the drug substance manufacturing process. Quality changes                                                | 19/02/2009   | 27/02/2009   |                                  | Approval of changes to the drug substance manufacturing process.                                                                                                                                                                                                                                                                                                                                                                                                |
| R/0028    | Renewal of the marketing authorisation.                                                                                         | 18/12/2008   | 26/02/2009   | SmPC, Annex II, Labelling and PL | Based upon the data that have become available since the granting of the initial Marketing Authorisation, the CHMP considers that the benefit/risk balance of Advate remains positive, but considers that its safety profile is to be closely monitored for the following reasons: - to follow the implementation of the registry/surveillance system further to the findings of the pharmacovigilance Inspection - to ensure appropriate implementation of the |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                    |            |            |                        | pharmacovigilance system / risk management plan The CHMP is of the opinion that one additional five-year renewal on the basis of pharmacovigilance grounds is required.                                                                                                                                                                                  |
|---------|----------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0031 | Change of specifications of reagent used in drug substance purification. Quality changes           | 22/01/2009 | 26/01/2009 |                        | Change of specifications of reagent used in drug substance purification.                                                                                                                                                                                                                                                                                 |
| IA/0029 | IA_05_Change in the name and/or address of a manufacturer of the finished product                  | 25/09/2008 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                          |
| IB/0027 | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient | 30/05/2008 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                          |
| X/0023  | Annex I_2.(c) Change or addition of a new strength/potency                                         | 19/03/2008 | 22/05/2008 | SmPC, Labelling and PL | The MAH applied for the approval of two additional strengths: 2000 and 3000 IU/vial. The composition of the new strengths does not differ from the compositon of the currently licensed dosage strengths, except for the amount of recombinant coagulation factor VIII. The overall benefit/risk ratio for the two new strengths is considered positive. |
| II/0026 | Quality changes                                                                                    | 21/02/2008 | 28/02/2008 |                        |                                                                                                                                                                                                                                                                                                                                                          |
| II/0025 | Update of or change(s) to the pharmaceutical documentation                                         | 13/12/2007 | 21/12/2007 |                        |                                                                                                                                                                                                                                                                                                                                                          |
| II/0024 | Quality changes                                                                                    | 15/11/2007 | 22/11/2007 |                        |                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| II/0022   | Update of Summary of Product Characteristics and Package Leaflet                                   | 21/06/2007   | 24/07/2007   | SmPC and PL                      | The MAH applied for a type II variation, upon request from the CHMP following a class review of recombinant Factor VIII medicinal products, to update section 4.4 of the SPC to include a warning on cases of inhibitors as follows: 'Cases of recurrence of inhibitors (low titre) have been observed after switching from one recombinant factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development.' The Package Leaflet has been updated accordingly.   |
|-----------|----------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0020   | Quality changes                                                                                    | 22/03/2007   | 28/03/2007   |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0021   | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient | 20/03/2007   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0019   | Update of Summary of Product Characteristics, Labelling and Package Leaflet                        | 14/12/2006   | 17/01/2007   | SmPC, Annex II, Labelling and PL | The MAH applied for an update of the SPC to Section 4.8 undesirable effects, following integrated analysis of safety data across all completed and ongoing clinical trials with corresponding amendments to the Package Leaflet. In addition, changes were implemented in all annexes in compliance with the latest QRD template.                                                                                                                                                                                                            |
| II/0018   | Quality changes                                                                                    | 14/12/2006   | 17/01/2007   | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0016   | Quality changes                                                                                    | 24/08/2006   | 11/09/2006   |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| N/0017    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   | 03/08/2006   | n/a          | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| II/0015   | Change(s) to the manufacturing process for the active substance Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                                                               | 23/03/2006   | 27/03/2006   |                        |                                                              |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|--------------------------------------------------------------|
| II/0012   | Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 26/01/2006   | 02/02/2006   |                        |                                                              |
| II/0014   | Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 17/11/2005   | 22/11/2005   |                        |                                                              |
| II/0009   | The Marketing Authorisation Holder applied for changes to the reconstitution device (BAXJET) used to transfer the solvent into the finished product vial and the reconstituted product into the syringe. The new device is called BAXJET II. In addition, the other ancillaries are removed from the pack containing the medicinal product (i.e. 1 x mini infusion set, 1 x 10 ml sterile disposable syringe, 2 x alcohol swabs, 2 x plasters). Change(s) to (an) ancillary medical device(s) | 13/10/2005   | 15/11/2005   | SmPC, Labelling and PL | This change has no impact on the medical use of the product. |
| II/0013   | Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 14/12/2005   | 20/10/2005   |                        |                                                              |
| IB/0011   | IB_37_a_Change in the specification of the finished product - tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                              | 31/08/2005   | n/a          |                        |                                                              |
| IA/0010   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                                                                                                                                                                                                            | 12/08/2005   | n/a          | Annex II               |                                                              |

<div style=\"page-break-after: always\"></div>

| II/0008   | Quality changes                                                            | 26/05/2005   | 01/06/2005   |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|----------------------------------------------------------------------------|--------------|--------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0006   | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale | 03/05/2005   | n/a          |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0007   | IA_09_Deletion of manufacturing site                                       | 22/03/2005   | n/a          |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0004   | Extension of Indication                                                    | 18/11/2004   | 21/12/2004   | SmPC, Labelling and PL | Introduction In this variation the MAH presented additional data from a phase 2/3 study (protocol 060101) on pharmacokinetics, immunogenicity, efficacy and safety in the use of Advate in previously treated paediatric patients (PTPs) with haemophilia A. Based on the data analysed the MAH sought an extension of the existing clinical indication to include children under the age of 6 and proposed to delete the following sentence \"Currently there are insufficient data in children less than 6 years of age to recommend the use of ADVATE.\" in section 4.2 of the SPC and corresponding changes in the PL. Further, the MAH proposed to amend sections 4.8 and 5.2 of the SPC. Consequential changes have been introduced in the PL. The MAH also took this opportunity to bring Annex III in line with the latest QRD template. Description of study 060101 This is an ongoing, multi-centre, open-label, prospective, uncontrolled clinical study of at least 50 paediatric PTPs under 6 years of age with severe or moderately severe haemophilia A (baseline factor VIII = 2%). |

<div style=\"page-break-after: always\"></div>

|         |                                               |            |            | - Part 1 is an open-label evaluation of the pharmacokinetics and short-term safety of Advate following a single dose of 50 Â± 5 IU/kg body weight; - Part 2 is an open-label determination of the immunogenicity, haemostatic efficacy, and safety of Advate. Subjects are to continue to receive Advate for at least 50 exposure days or a total treatment time of 6 months, whichever comes first. The treatment regimen is determined by the site investigator (i.e., standard prophylaxis [25 to 50 IU/kg, 3 to 4 times per week], modified prophylaxis, or on-demand treatment). Results and discussion Over the 18-month period covered by the interim report, 53 paediatric PTPs < 6 years of age were given a single infusion of Advate in Part 1 of this study for the determination of pharmacokinetic and safety data parameters. Forty of these subjects have been seen for at   |
|---------|-----------------------------------------------|------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0003 | Quality changes                               | 16/09/2004 | 22/09/2004 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0001 | Change(s) to shelf-life or storage conditions | 29/07/2004 | 04/08/2004 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |